276 related articles for article (PubMed ID: 27834845)
1. The Receptor Tyrosine Kinase AXL in Cancer Progression.
Rankin EB; Giaccia AJ
Cancers (Basel); 2016 Nov; 8(11):. PubMed ID: 27834845
[TBL] [Abstract][Full Text] [Related]
2. Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment.
Tanaka M; Siemann DW
Cancers (Basel); 2020 Jul; 12(7):. PubMed ID: 32660000
[TBL] [Abstract][Full Text] [Related]
3. Immune Evasion Mechanism and AXL.
Son HY; Jeong HK
Front Oncol; 2021; 11():756225. PubMed ID: 34778071
[TBL] [Abstract][Full Text] [Related]
4. AXL receptor tyrosine kinase as a therapeutic target in NSCLC.
Okimoto RA; Bivona TG
Lung Cancer (Auckl); 2015; 6():27-34. PubMed ID: 28210148
[TBL] [Abstract][Full Text] [Related]
5. AXL Receptor Tyrosine Kinase as a Therapeutic Target in Hematological Malignancies: Focus on Multiple Myeloma.
Yan S; Vandewalle N; De Beule N; Faict S; Maes K; De Bruyne E; Menu E; Vanderkerken K; De Veirman K
Cancers (Basel); 2019 Nov; 11(11):. PubMed ID: 31694201
[TBL] [Abstract][Full Text] [Related]
6. AXL Receptor in Cancer Metastasis and Drug Resistance: When Normal Functions Go Askew.
Auyez A; Sayan AE; Kriajevska M; Tulchinsky E
Cancers (Basel); 2021 Sep; 13(19):. PubMed ID: 34638349
[TBL] [Abstract][Full Text] [Related]
7. AXL Receptor Tyrosine Kinase as a Promising Therapeutic Target Directing Multiple Aspects of Cancer Progression and Metastasis.
Goyette MA; Côté JF
Cancers (Basel); 2022 Jan; 14(3):. PubMed ID: 35158733
[TBL] [Abstract][Full Text] [Related]
8. Gas6/AXL pathway: immunological landscape and therapeutic potential.
Zhai X; Pu D; Wang R; Zhang J; Lin Y; Wang Y; Zhai N; Peng X; Zhou Q; Li L
Front Oncol; 2023; 13():1121130. PubMed ID: 37265798
[TBL] [Abstract][Full Text] [Related]
9. AXL as a Target in Breast Cancer Therapy.
Colavito SA
J Oncol; 2020; 2020():5291952. PubMed ID: 32148495
[TBL] [Abstract][Full Text] [Related]
10. Function of Axl receptor tyrosine kinase in non-small cell lung cancer.
Zhang G; Wang M; Zhao H; Cui W
Oncol Lett; 2018 Mar; 15(3):2726-2734. PubMed ID: 29434997
[TBL] [Abstract][Full Text] [Related]
11. Engineered AXL
Duan Y; Hu B; Qiao C; Luo L; Li X; Wang J; Liu H; Zhou T; Shen B; Lv M; Feng J
Oncol Lett; 2019 Jun; 17(6):5784-5792. PubMed ID: 31186805
[TBL] [Abstract][Full Text] [Related]
12. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications.
Wium M; Ajayi-Smith AF; Paccez JD; Zerbini LF
Cancers (Basel); 2021 Mar; 13(7):. PubMed ID: 33806258
[TBL] [Abstract][Full Text] [Related]
13. The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges.
Sang YB; Kim JH; Kim CG; Hong MH; Kim HR; Cho BC; Lim SM
Front Oncol; 2022; 12():811247. PubMed ID: 35311091
[TBL] [Abstract][Full Text] [Related]
14. Axl inhibition induces the antitumor immune response which can be further potentiated by PD-1 blockade in the mouse cancer models.
Guo Z; Li Y; Zhang D; Ma J
Oncotarget; 2017 Oct; 8(52):89761-89774. PubMed ID: 29163786
[TBL] [Abstract][Full Text] [Related]
15. AXL and MET in Hepatocellular Carcinoma: A Systematic Literature Review.
Hsu CH; Huang YH; Lin SM; Hsu C
Liver Cancer; 2022 Apr; 11(2):94-112. PubMed ID: 35634427
[TBL] [Abstract][Full Text] [Related]
16. Gas6/Axl pathway is activated in chronic liver disease and its targeting reduces fibrosis via hepatic stellate cell inactivation.
Bárcena C; Stefanovic M; Tutusaus A; Joannas L; Menéndez A; García-Ruiz C; Sancho-Bru P; Marí M; Caballeria J; Rothlin CV; Fernández-Checa JC; de Frutos PG; Morales A
J Hepatol; 2015 Sep; 63(3):670-8. PubMed ID: 25908269
[TBL] [Abstract][Full Text] [Related]
17. Ligand Activation of TAM Family Receptors-Implications for Tumor Biology and Therapeutic Response.
Davra V; Kimani SG; Calianese D; Birge RB
Cancers (Basel); 2016 Nov; 8(12):. PubMed ID: 27916840
[TBL] [Abstract][Full Text] [Related]
18. Gas6/Axl signaling activates the phosphatidylinositol 3-kinase/Akt1 survival pathway to protect oligodendrocytes from tumor necrosis factor alpha-induced apoptosis.
Shankar SL; O'Guin K; Kim M; Varnum B; Lemke G; Brosnan CF; Shafit-Zagardo B
J Neurosci; 2006 May; 26(21):5638-48. PubMed ID: 16723520
[TBL] [Abstract][Full Text] [Related]
19. Altered expression of AXL receptor tyrosine kinase in gastrointestinal cancers: a promising therapeutic target.
Pidkovka N; Belkhiri A
Front Oncol; 2023; 13():1079041. PubMed ID: 37469409
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic Targeting of AXL Receptor Tyrosine Kinase Inhibits Tumor Growth and Intraperitoneal Metastasis in Ovarian Cancer Models.
Kanlikilicer P; Ozpolat B; Aslan B; Bayraktar R; Gurbuz N; Rodriguez-Aguayo C; Bayraktar E; Denizli M; Gonzalez-Villasana V; Ivan C; Lokesh GLR; Amero P; Catuogno S; Haemmerle M; Wu SY; Mitra R; Gorenstein DG; Volk DE; de Franciscis V; Sood AK; Lopez-Berestein G
Mol Ther Nucleic Acids; 2017 Dec; 9():251-262. PubMed ID: 29246304
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
